Affordable Access

Active immunotherapy in follicular lymphoma.

Authors
  • Veelken, Hendrik
Type
Published Article
Journal
Seminars in cancer biology
Publication Date
Jun 01, 2003
Volume
13
Issue
3
Pages
241–247
Identifiers
PMID: 12959355
Source
Medline
License
Unknown

Abstract

The antigen receptors expressed by follicular lymphomas represent tumor-specific antigens ("idiotypes"). In murine models, vaccination with tumor-derived idiotype in a variety of formulations can induce protective lymphoma-specific immunity. Phase II clinical trials in follicular lymphoma have also demonstrated idiotype-specific immune responses. Clinical data from these trials indicate sustained progression-free survival, disappearance of minimal residual disease, and even frank lymphoma regression in some cases. Phase III trials to prove the beneficial effects of active immunotherapy are currently being conducted. Additional research efforts focus on the most efficacious vaccination route and on the development of convenient methods to manufacture individual idiotype vaccines.

Report this publication

Statistics

Seen <100 times